// App-Quantinova.ai

656 : Exploratory platform trial to evaluate immunotherapy combinations with chemotherapy for the treatment of patients with previously untreated metastatic pancreatic adenocarcinoma (REVOLUTION)

Researchers

Presenter

  • Jaclyn Lyman

Principal Investigators

  • Zev Wainberg

  • George Fisher

  • Robert Wolff

  • Andrew Ko

  • Mark O’Hara

  • Harshabad Singh

  • Ravi Amaravadi

  • Alec Kimmelman

  • Eric Collison

  • Danny Khalil

  • Rosemarie Schmidberger

  • Christopher Cabanski

  • Stephen Maddock

  • Marko Spasic

  • Deena Maurer

  • Diane Da Silva

  • Christopher Perry

  • Jia Xin Yu

  • Lacey Padron

  • Samantha Bucktrout

  • Lisa Butterfield

  • Ramy Ibrahim

  • Justin Fairchild

  • Theresa LaVallee

  • Thomas Lillie

  • William Hoos

  • Silvia Boffo

  • Ute Dugan

  • Jill O’Donnell-Tormey

  • Robert Vonderheide

Medical Centers

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Dana-Farber Cancer Institute, Boston, MA

  • Cancer Research Institute, New York, NY

  • University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA

  • University of California, Los Angeles, Los Angeles, CA

  • Stanford University, San Francisco, CA, USA

  • New York University School of Medicine/NYU Perlmutter Cancer Center, New York, NY

  • PsiOxus Therapeutics, Ltd, Abingdon, UK

  • University of California, San Francisco, San Francisco, CA

  • Foundation, Scotts Valley, CA, USA

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • Parker Institute for Cancer Immunotherapy, San Francisco, CA

  • 1.MD Anderson Cancer Center, Houston, TX

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Metastatic pancreatic adenocarcinoma

Biomarkers

  • Cluster of Differentiation 40

Drug/Treatment

  • Hydroxychloroquine

  • Gemcitabine

  • Ipilimumab

  • Paclitaxel

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacodynamics

  • Open Label

  • Cohort

Phase

  • NA

Study Id's

  • NCT04787991

Sponsors

  • Cancer Research Institute

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved